Betta Pharmaceuticals vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Betta Pharmaceuticals Co Ltd (300558.CS)

Q3 20269 Jul – 3 Sep 2026

▲4

Betta's lung cancer drug wins key approvals as profit doubles

Ensartinib adjuvant approval expands market China approved ensartinib for adjuvant treatment of ALK-positive lung cancer after surgery, making it only the second such drug globally. This opens a new patient group and should lift future sales, though the company warns actual uptake is uncertain.
New regulatory approval directly expands the drug's addressable market and revenue potential.
Strong NEJM data backs ensartinib The ELEVATE study showed ensartinib cut the risk of lung cancer returning or death by 80% versus placebo. Publication in a top medical journal builds doctor confidence and supports the drug's use, helping drive prescriptions and sales.
High-quality clinical evidence is a key driver of adoption and pricing power for a new drug.
Bevacizumab added to essential medicines list Bevacizumab joined China's National Essential Medicines List, which helps it reach more hospitals and primary care. This should boost sales volume, though the list can also bring price pressure over time.
List inclusion is a direct demand driver for an existing product.
Interim profit more than doubles First-half net profit rose 116% to 302 million yuan on 14% higher revenue, with earnings per share up 118%. The strong profit growth shows the business is scaling and supports a higher share price, though cash flow slipped slightly.
Profit growth is a core fundamental driver of stock valuation.

August 20269 Jul – 3 Sep 2026

▲4

Betta's lung cancer drug wins key approvals as profit doubles

Ensartinib adjuvant approval expands market China approved ensartinib for adjuvant treatment of ALK-positive lung cancer after surgery, making it only the second such drug globally. This opens a new patient group and should lift future sales, though the company warns actual uptake is uncertain.
New regulatory approval directly expands the drug's addressable market and revenue potential.
Strong NEJM data backs ensartinib The ELEVATE study showed ensartinib cut the risk of lung cancer returning or death by 80% versus placebo. Publication in a top medical journal builds doctor confidence and supports the drug's use, helping drive prescriptions and sales.
High-quality clinical evidence is a key driver of adoption and pricing power for a new drug.
Bevacizumab added to essential medicines list Bevacizumab joined China's National Essential Medicines List, which helps it reach more hospitals and primary care. This should boost sales volume, though the list can also bring price pressure over time.
List inclusion is a direct demand driver for an existing product.
Interim profit more than doubles First-half net profit rose 116% to 302 million yuan on 14% higher revenue, with earnings per share up 118%. The strong profit growth shows the business is scaling and supports a higher share price, though cash flow slipped slightly.
Profit growth is a core fundamental driver of stock valuation.

Latest9 Jul – 3 Sep 2026

▲4

Betta's lung cancer drug wins key approvals as profit doubles

Ensartinib adjuvant approval expands market China approved ensartinib for adjuvant treatment of ALK-positive lung cancer after surgery, making it only the second such drug globally. This opens a new patient group and should lift future sales, though the company warns actual uptake is uncertain.
New regulatory approval directly expands the drug's addressable market and revenue potential.
Strong NEJM data backs ensartinib The ELEVATE study showed ensartinib cut the risk of lung cancer returning or death by 80% versus placebo. Publication in a top medical journal builds doctor confidence and supports the drug's use, helping drive prescriptions and sales.
High-quality clinical evidence is a key driver of adoption and pricing power for a new drug.
Bevacizumab added to essential medicines list Bevacizumab joined China's National Essential Medicines List, which helps it reach more hospitals and primary care. This should boost sales volume, though the list can also bring price pressure over time.
List inclusion is a direct demand driver for an existing product.
Interim profit more than doubles First-half net profit rose 116% to 302 million yuan on 14% higher revenue, with earnings per share up 118%. The strong profit growth shows the business is scaling and supports a higher share price, though cash flow slipped slightly.
Profit growth is a core fundamental driver of stock valuation.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.